Abbott Vascular Devices Limited, a subsidiary of Abbott Laboratories, is a leading player in the global medical device industry, specialising in innovative cardiovascular solutions. Headquartered in Great Britain, the company operates extensively across Europe, North America, and Asia, focusing on enhancing patient outcomes through advanced technology. Founded in the early 2000s, Abbott Vascular has achieved significant milestones, including the development of cutting-edge stent systems and catheter-based interventions. Their core products, such as drug-eluting stents and transcatheter heart valves, are distinguished by their unique designs and efficacy in treating complex cardiovascular conditions. With a strong market position, Abbott Vascular is recognised for its commitment to research and development, consistently delivering high-quality products that set industry standards. The company’s dedication to innovation and patient care solidifies its reputation as a trusted leader in the vascular device sector.
How does Abbott Vascular Devices Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Abbott Vascular Devices Limited's score of 49 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Abbott Vascular Devices Limited, headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Abbott Laboratories, which cascades its climate commitments and performance metrics down to its subsidiaries. Abbott Laboratories has set ambitious climate targets, which include commitments to reduce greenhouse gas emissions across its operations. These targets are aligned with the Science Based Targets initiative (SBTi) and are part of a broader strategy to enhance sustainability within the healthcare sector. However, specific reduction targets or achievements for Abbott Vascular Devices Limited have not been disclosed. As a subsidiary, Abbott Vascular Devices Limited is expected to adhere to the sustainability initiatives and performance standards established by Abbott Laboratories, which may include efforts to improve energy efficiency and reduce emissions in line with industry best practices. The company is positioned within a corporate family that prioritises climate action, although detailed metrics specific to its operations remain unavailable.
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 578,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 691,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - | - | - | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Abbott Vascular Devices Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.